Heather Dworak
Company: Sunovion
Job title: Senior Director, Clinical Research
Seminars:
Live Q&A 1:20 pm
day: Day One
Development of SEP-363856, a TAAR1/5-HT1A Agonist for the Treatment of Schizophrenia 11:50 am
• Summary of the discovery of SEP-363856 and its novel non-D2 based mechanism of action for the treatment of schizophrenia • Rationale for development of a non-D2 agent for the treatment of schizophrenia: importance and implications • Overview of clinical trial data to date, and status update of our Phase 3 clinical development programRead more
day: Day One